Ondine To Launch Ventilator-Associated Pneumonia (VAP) Photodisinfection Clinical Study

We are thrilled to announce that the FDA has approved a human clinical study to investigate the use of photodisinfection to prevent ventilator-associated pneumonia (VAP). VAP occurs when a lung infection develops in a patient ventilated with an endotracheal tube and continues to be the #1 cause of healthcare-associated infections in intensive care units. In the U.S alone, more than 1.3 million patients are mechanically ventilated every year. Of these patients, 10%-20% will develop ventilator-associated pneumonia, and up to half of them will die.

“A successful VAP study would represent a key step towards the commercialization of this new application of photodisinfection which utilizes Ondine’s patented technology and products…(our technology) has been proven to be highly effective at eliminating biofilms in ex vivo models, it is therefore ideally suited for the elimination of endotracheal tube biofilms resulting in the prevention of VAP” says Carolyn Cross, Chairman & CEO of Ondine.

The presence of an endotracheal tube inserted into a patient’s body increases their risk of developing a serious infection since the natural protective barriers of the body have been bypassed. Microorganisms and antibiotic-resistant biofilm found on the surface of the tube now have direct access to the lungs, which can result in life-threatening cases of VAP. This study will explore the use of photodisinfection as a non-antibiotic, non-invasive approach to eradicate the endotracheal tube of harmful bacteria without removing it from the body.

We are very excited to further investigate the use of our technology in the prevention of ventilator-associated pneumonia. To learn more about photodisinfection, please read this guest blog post by Merrill Biel, MD, PhD, MBA.

Related Posts Plugin for WordPress, Blogger...

Leave a Reply

Staypressed theme by Themocracy